Wuxi’s Q2 Revenue Jumps as China Lab Services Drive Growth

By Zachary Brennan

- Last updated on GMT

Related tags Revenue

Wuxi’s Q2 Revenue Jumps as China Lab Services Drive Growth
CRO Wuxi’s Q2 net revenue increased by almost 10% compared to the same quarter last year as its China-based lab services grew by almost 20%.

Revenues from biologics services grew strongly in the second quarter and will be one of the key drivers of revenue and earnings growth for the next several years​,” Dr. Ge Li, chairman and CEO of Wuxi said. “Commercial manufacturing has a growing pipeline of products, several of which have received breakthrough designation by the US FDA​.”

Revenue growth and gross margin in laboratory services was driven by Wuxi’s improved productivity and the ramp-up of biologics and preclinical services, though that was slightly offset by increasing Chinese labor costs and appreciation of the renminbi versus the US dollar, the company said.  

But a revenue decline of 1.1% in manufacturing services was the result of lower demand compared to a record level achieved in Q2 of 2012.

As far as the company’s joint venture with PRA, which recently announced a president​, CFO Edward Hu said it’s just beginning to kick off and even if it is able to win a large clinical project today, because China’s clinical trial approval process takes so long, it would take at least six months to get started. “But it has a great pipeline ahead starting from next year​,” he added.

Future Outlook

Wuxi also raised its revenue and EPS (earnings per share) guidance for the rest of the year

CFO Edward Hu said the company’s China-based lab services typically see its highest margins in Q4 because clients generally want to finish their projects before the end of the year, according to a Seeking Alpha transcript​ of the earnings call on Tuesday.

Our strong second-quarter performance gives us confidence to increase full-year 2013 revenue guidance to $572-$578 million and full-year 2013 diluted EPS guidance to $1.38-$1.44 GAAP and $1.61-$1.67 non-GAAP​,” Dr. Li said.

Analysts Upbeat

Analysts also seem to remain upbeat about Wuxi’s prospects, with Jefferies’ David Windley calling the company “one of the more consistent CRO performers​,” and also “the cheapest of the CROs despite its favourable growth outlook​.”

William Blair analyst John Kreger added that compared to its Western CRO counterparts, the stock still trades at a significant discount. 

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us

Webinars

Headlines